Castle Biosciences Inc expected to post a loss of 84 cents a share - Earnings Preview

Castle Biosciences

25/02/2023 03:09

* Castle Biosciences Inc  CSTL.OQ   CSTL.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
28. 
    * The Friendswood Texas-based  company is expected to report
 a
48.4% increase in revenue to $37.156 million from $25.04 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Castle Biosciences
Inc is
for a loss of 84 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $48.5​, above​ its last closing price
of $24.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.92       -0.88      -0.77     Beat    12.5
 Jun. 30 2022  -0.77       -0.76      -0.06     Beat    92.1
 Mar. 31 2022  -0.70       -0.71      -0.97     Missed  -37.2​
 Dec. 31 2021  -0.48       -0.47      -0.25     Beat    46.8
 ​​Sep.        -0.43       -0.40      -0.47     Missed  -16
 30 2021                                                
 Jun. 30 2021  -0.40       -0.37      -0.34     Beat    7.1​
 Mar. 31 2021  -0.24       -0.23      -0.17     Beat    27.7
 Dec. 31 2020  -0.12       -0.12      -0.17     Missed  -39.3
 This summary was machine generated February 25 at 03:09 GMT. 
All figures in US dollars  unless otherwise stated